Litcius/Paper detail

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, James R. Kiefer, Melissa M. Schutten, Adeyemi O. Adedeji, Hao Cai, Robert L. Hendricks, Sivan Cohen, Srividya Myneni, Luna Liu, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida Nagata, Shelly Zhong, Steven R. Leong, Ji Li, Rin Nakamura, Teiko Sumiyoshi, Jinze Li, Ayse Meric Ovacik, Bing Zheng, Mike Dillon, Christoph Spiess, Susanne Wingert, Erich Rajkovic, Kristina Ellwanger, Uwe Reusch, Andrew G. Polson

2022Leukemia41 citationsDOI

Topics & Concepts

TolerabilityDaratumumabCytotoxicityCancer researchLysisAntibodyImmunologyMonoclonal antibodyChemistryMolecular biologyBiologyIn vitroPharmacologyBiochemistryAdverse effectMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchComplement system in diseases
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma | Litcius